The new Covid-19 bivalent booster vaccine is reportedly provides “substantially higher” protection against Omicron BA.4/BA.5 subvariants in peoples compared to the original Covid-19 vaccine, writes CNN quoting the company’s two small studies.
CNN writes that the Pfizer and BioNTech’s new data are not published and not peer-reviewed as well. “When someone gets any vaccine, it can take a few weeks to build up immunity and generate its full protection. The data showed that a month after study participants got the new booster, Omicron BA.4/BA.5 neutralizing antibodies increased 13.2 fold from pre-booster levels for the adults 55 and older, compared with a 2.9 fold increase in older adults who got the original vaccine. For adults ages 18 to 55, neutralizing antibodies were 9.5 fold higher than pre-booster levels.”
CNN quoting Pfizer CEO Albert Bourla’s statement writes “As we head into the holiday season, we hope these updated data will encourage people to seek out a COVID-19 bivalent booster as soon as they are eligible in order to maintain high levels of protection against the widely circulating Omicron BA.4 and BA.5 sublineages. These updated data also provide confidence in the adaptability of our mRNA platform and our ability to rapidly update the vaccine to match the most prevalent strains each season.”
Pfizer and BioNTech told CNN that they are still conducting larger clinical trials of the updated boosters, and are continuing to test the vaccine against the other variants of the virus.
Health experts advised people get booster vaccine to get protected from the Covid-19 subvariants that are expected to spread during the winter season.
